Newly available treatments for nicotine addictionBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7294.1076 (Published 05 May 2001) Cite this as: BMJ 2001;322:1076
- Tim Coleman (), senior lecturer,
- Robert West, professor of psychology
- Department of General Practice and Primary Health Care, Leicester Warwick Medical School, Leicester General Hospital, Leicester LE5 4PW
- Psychology Department, St George's Hospital Medical School, London SW17 0RE
Nicotine addiction is recognised as a life threatening but treatable disorder1 and from 17 April, in accordance with the NHS Plan, all forms of nicotine replacement therapy were made available on NHS prescription.2 Britain now has a comprehensive treatment strategy for nicotine addiction, which includes provision of bupropion (Zyban) on prescription3 and the introduction of specialist smoking cessation services to provide behavioural support to people who want to stop smoking.4
In theory therefore, every smoker in the country who wants help with overcoming his or her addiction to nicotine now has access to effective treatments. Many general practitioners, however, are sceptical about the appropriateness of having nicotine replacement therapy or bupropion available on NHS prescription,5 and many are unaware of the part these can play in helping smokers to stop. The Health Development Agency is distributing a reprint of guidelines on smoking cessation with the general practice edition of this week's BMJ,6 and here we summarise the evidence on the effectiveness of nicotine replacement therapy, bupropion, and behavioural support to guide prescribing and referral decisions.
Nicotine replacement therapy used alone can be effective, but better results are achieved when it is combined with behavioural support and counselling from a trained health professional.6 More intensive support seems to be more effective.6 For example, nicotine replacement therapy prescribed after general practitioners' brief advice against smoking can result in up to 10% of smokers stopping,6 but nicotine replacement therapy together with support from specialist counsellors can result in up to 20% of smokers stopping.6 Bupropion has not yet been tested without intensive behavioural support, so it is difficult to know whether it can be effective without this. The sustained one year abstinence rates achieved in the published trials of bupropion average about 20%. 7 8 Nicotine replacement therapy is generally well tolerated, and most side effects arise from the irritant effect of nicotine (such as rashes with nicotine patches). Experience from many years' use of bupropion in the United States indicates that, in the dose used for smoking cessation, it causes seizures in about 1 in 1000 users, and figures from initial use in the UK are consistent with this.9 The most common side effects, however, are relatively minor, with insomnia and dry mouth the commonest.
How should this evidence translate into clinical practice? Firstly, nicotine replacement therapy and bupropion are suitable only for heavier smokers (10-15 a day or more) who clearly want to stop and are ready to try. Indiscriminate prescribing to unselected smokers is unlikely to be effective. Secondly, smokers who want to try stopping should be offered referral to the newly established specialist services. Thirdly, if for some reason a smoker cannot attend the service it is still worth offering a prescription for nicotine replacement therapy.
Smoking cessation services should now be running in all health authorities. These can provide specialist behavioural support to maximise smokers' chances of stopping and are being geared to meet local needs, so most smokers should have relatively convenient access to them. Once smokers are referred general practitioners should work with the specialist services to ensure that patients receive the medication they need. In addition to treating smokers, services have a brief to train health professionals, so interested primary care teams may be able to obtain training in smoking cessation methods, enabling them to provide some support to smokers within general practices.
The costs of prescribing nicotine replacement therapy or bupropion are likely to remain modest. Currently, in an average general practitioners' list of 2000 patients only around five smokers a year are using the specialist smoking cessation services together with nicotine replacement therapy or bupropion.10 Additionally, the Department of Health has increased prescribing budgets to allow for more prescriptions of nicotine replacement therapy and bupropion. This money may not be obvious, however, as it has not been ring fenced. Also, from April 2002 the money to fund specialist smoking cessation services will no longer be ring fenced and services will be commissioned from within primary care.11 It is essential that the government continues to provide adequate funds to sustain services and that health authorities, primary care groups, and primary care trusts liase with their local smoking cessation services to arrange for their continued provision.
The UK has led the world by establishing a national network of smoking cessation services using proved treatments. It would be unpardonable if these were to be lost in the transition between funding arrangements.
TC has been paid for speaking at an event organised by the manufacturers of bupropion. RW has undertaken research and consultancy for and received travel funds from manufacturers of nicotine replacement therapies and bupropion.